This population-based retrospective study provides such evidence to policymakers and other stakeholders by drawing a portrait of advanced lung cancer patients who received EGFR-TKIs that are publicly covered in Quebec for specific indications and comparing estimates of OS in this population to those published in RCTs and real-world studies. Here, EGFR is linked to lung carcinoma.